La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

RHÖN-KLINIKUM Crescita futura

Future criteri di controllo 1/6

RHÖN-KLINIKUM prevede che gli utili e i ricavi cresceranno rispettivamente di 5.1% e 2% all'anno. Si prevede che l'EPS crescerà di 8.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 3.4% in 3 anni.

Informazioni chiave

5.1%

Tasso di crescita degli utili

8.3%

Tasso di crescita dell'EPS

Healthcare crescita degli utili	20.3%
Tasso di crescita dei ricavi	2.0%
Rendimento futuro del capitale proprio	3.4%
Copertura analitica	Low
Ultimo aggiornamento	29 Jul 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

RHÖN-KLINIKUM Aktiengesellschaft's (ETR:RHK) Business Is Trailing The Market But Its Shares Aren't

Jun 26

RHÖN-KLINIKUM (ETR:RHK) Seems To Use Debt Rather Sparingly

Apr 25

RHÖN-KLINIKUM Aktiengesellschaft (ETR:RHK) Stocks Shoot Up 27% But Its P/E Still Looks Reasonable

Mar 02

Is RHÖN-KLINIKUM (ETR:RHK) Using Too Much Debt?

Dec 19

Here's Why RHÖN-KLINIKUM (ETR:RHK) Can Manage Its Debt Responsibly

Jul 13

There Are Reasons To Feel Uneasy About RHÖN-KLINIKUM's (ETR:RHK) Returns On Capital

Jun 15

These 4 Measures Indicate That RHÖN-KLINIKUM (ETR:RHK) Is Using Debt Reasonably Well

Sep 20

Previsioni di crescita degli utili e dei ricavi

XTRA:RHK - Stime future degli analisti e dati finanziari passati (EUR Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	1,657	50	28	107	2
12/31/2025	1,596	44	25	99	2
12/31/2024	1,534	39	39	110	2
6/30/2024	1,802	47	69	142	N/A
3/31/2024	1,767	43	N/A	N/A	N/A
12/31/2023	1,735	39	46	109	N/A
9/30/2023	1,713	32	N/A	N/A	N/A
6/30/2023	1,694	26	-11	43	N/A
3/31/2023	1,690	30	N/A	N/A	N/A
12/31/2022	1,661	25	2	60	N/A
9/30/2022	1,640	30	N/A	N/A	N/A
6/30/2022	1,628	32	-18	48	N/A
3/31/2022	1,602	28	N/A	N/A	N/A
12/31/2021	1,591	28	20	98	N/A
9/30/2021	1,557	15	N/A	N/A	N/A
6/30/2021	1,554	14	23	117	N/A
3/31/2021	1,549	7	N/A	N/A	N/A
12/31/2020	1,546	1	16	113	N/A
9/30/2020	1,537	8	20	113	N/A
6/30/2020	1,532	19	10	100	N/A
3/31/2020	1,513	31	-28	63	N/A
12/31/2019	1,481	43	-67	47	N/A
9/30/2019	1,436	40	-61	91	N/A
6/30/2019	1,413	52	-95	74	N/A
3/31/2019	1,394	47	-134	46	N/A
12/31/2018	1,390	49	-114	50	N/A
9/30/2018	1,411	55	-114	24	N/A
6/30/2018	1,385	36	-76	54	N/A
3/31/2018	1,374	37	N/A	63	N/A
12/31/2017	1,362	35	N/A	80	N/A
9/30/2017	1,340	2	N/A	69	N/A
6/30/2017	1,330	4	N/A	87	N/A
3/31/2017	1,334	14	N/A	96	N/A
12/31/2016	1,319	56	N/A	109	N/A
9/30/2016	1,291	101	N/A	114	N/A
6/30/2016	1,276	105	N/A	101	N/A
3/31/2016	1,251	103	N/A	80	N/A
12/31/2015	1,240	85	N/A	67	N/A
9/30/2015	1,250	66	N/A	63	N/A
6/30/2015	1,248	62	N/A	54	N/A
3/31/2015	1,300	-138	N/A	55	N/A
12/31/2014	1,666	1,226	N/A	49	N/A
9/30/2014	2,171	1,245	N/A	67	N/A
6/30/2014	2,661	1,250	N/A	153	N/A
3/31/2014	3,098	1,459	N/A	209	N/A
12/31/2013	3,223	87	N/A	210	N/A
9/30/2013	3,189	87	N/A	199	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di RHK ( 5.1% all'anno) è superiore al tasso di risparmio ( 0.8% ).

Guadagni vs Mercato: Si prevede che gli utili di RHK ( 5.1% all'anno) cresceranno più lentamente rispetto al mercato German ( 20% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di RHK cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di RHK ( 2% all'anno) crescerà più lentamente rispetto al mercato German ( 5.2% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di RHK ( 2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di RHK sarà basso tra 3 anni ( 3.4 %).

RHÖN-KLINIKUM Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased to €15.00

Price target decreased to €16.50

Consensus EPS estimates fall to €0.23

RHON-KLINIKUM AG Provides Revenue Guidance for the Year 2021

Recent updates

Second quarter 2024 earnings released: EPS: €0.14 (vs €0.09 in 2Q 2023)

RHÖN-KLINIKUM Aktiengesellschaft's (ETR:RHK) Business Is Trailing The Market But Its Shares Aren't

First quarter 2024 earnings released: EPS: €0.16 (vs €0.09 in 1Q 2023)

RHÖN-KLINIKUM (ETR:RHK) Seems To Use Debt Rather Sparingly

Investor sentiment improves as stock rises 17%

Full year 2023 earnings released: EPS: €0.58 (vs €0.38 in FY 2022)

RHÖN-KLINIKUM Aktiengesellschaft (ETR:RHK) Stocks Shoot Up 27% But Its P/E Still Looks Reasonable

Investor sentiment improves as stock rises 15%

Is RHÖN-KLINIKUM (ETR:RHK) Using Too Much Debt?

RHÖN-KLINIKUM Aktiengesellschaft to Report Q2, 2024 Results on Aug 08, 2024

Third quarter 2023 earnings released: EPS: €0.17 (vs €0.069 in 3Q 2022)

Second quarter 2023 earnings released: EPS: €0.09 (vs €0.16 in 2Q 2022)

Here's Why RHÖN-KLINIKUM (ETR:RHK) Can Manage Its Debt Responsibly

There Are Reasons To Feel Uneasy About RHÖN-KLINIKUM's (ETR:RHK) Returns On Capital

Upcoming dividend of €0.15 per share at 1.2% yield

Full year 2022 earnings released: EPS: €0.38 (vs €0.42 in FY 2021)

RHÖN-KLINIKUM Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 30, 2023

Price target decreased to €15.00

These 4 Measures Indicate That RHÖN-KLINIKUM (ETR:RHK) Is Using Debt Reasonably Well

Capital Allocation Trends At RHÖN-KLINIKUM (ETR:RHK) Aren't Ideal

Second quarter 2022 earnings released: EPS: €0.16 (vs €0.10 in 2Q 2021)

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to €16.50

Robust Earnings May Not Tell The Whole Story For RHÖN-KLINIKUM (ETR:RHK)

Third quarter 2021 earnings released: EPS €0.10 (vs €0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.10 (vs €0.003 in 2Q 2020)

Does RHÖN-KLINIKUM (ETR:RHK) Have A Healthy Balance Sheet?

First quarter 2021 earnings released: EPS €0.02 (vs €0.066 loss in 1Q 2020)

Consensus EPS estimates fall to €0.23

Full year 2020 earnings released: EPS €0.02 (vs €0.65 in FY 2019)

RHON-KLINIKUM AG Provides Revenue Guidance for the Year 2021

RHÖN-KLINIKUM Aktiengesellschaft to Report Q2, 2021 Results on Aug 05, 2021

RHÖN-KLINIKUM Aktiengesellschaft to Report Fiscal Year 2020 Results on Feb 25, 2021

New 90-day low: €15.50

New 90-day low: €16.10

RHÖN-KLINIKUM Aktiengesellschaft, Annual General Meeting, Jun 09, 2021

RHÖN-KLINIKUM Aktiengesellschaft to Report Q4, 2020 Final Results on Mar 25, 2021

Third quarter 2020 earnings released: EPS €0.09

RHÖN-KLINIKUM Aktiengesellschaft appoints Christian Höftberger as new CEO

Medgate Holding AG acquired remaining 51% stake in Medgate Deutschland GmbH from RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK).

RHÃ–N-KLINIKUM Aktiengesellschaft to Report Nine Months, 2020 Results on Nov 06, 2020

New 90-day low: €15.98

New 90-day low - €16.96

Upcoming Dividend of €0.25 Per Share

Asklepios Kliniken GmbH & Co. KGaA completed the acquisition of additional 42.5% stake in RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK) from HCM SE, B. Braun Melsungen AG, Landeskrankenhilfe V.V.A.G, Asset Management Arm and others for approximately €510 million.

Asklepios Kliniken GmbH concluded the acquisition of additional 12.4% stake in RHÖN-KLINIKUM Aktiengesellschaft (XTRA:RHK) from Eugen Münch and Ingeborg Münch.

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita